Abrocitinib proves efficacious in atopic dermatitis : JAMA study Dr Manoj Kumar Nayak2 Sept 2021 9:00 AM ISTAbrocitinib proves efficacious in atopic dermatitis finds a new study published in JAMA. Atopic dermatitis (AD) is a severely pruritic chronic,...
Abrocitinib significantly improves moderate-to-severe atopic dermatitis;NEJM Dr Satabdi Saha19 April 2021 7:45 AM ISTAbrocitinib at a dose of either 200 mg or 100 mg once daily resulted in significantly greater reductions in signs and symptoms of moderate-to-severe...
Abrocitinib shows promise in managing severe atopic dermatitis;NEJM Dr Satabdi Saha5 April 2021 8:00 PM ISTA recent study has suggested that abrocitinib, at a dose of either 200 mg or 100 mg ,once daily, resulted in significantly greater reductions in signs...
Pfizer reports positive results from fifth phase 3 trial of Abrocitinib Ruchika Sharma13 Nov 2020 9:30 AM ISTNew York: Pfizer Inc. has recently announced positive top-line results from the Phase 3 JADE REGIMEN study. This 52-week study investigated...
Pfizer Abrocitinib hits mark in phase 3 of Atopic Dermatitis trial Ruchika Sharma14 Jun 2020 9:45 AM ISTAbrocitinib received Breakthrough Therapy designation from the FDA for the treatment of patients with moderate to severe AD in February 2018, Pfizer...
